When assessing the diagnostic usefulness of CA125 and HE4 levels in ovarian cancer, the researchers determined that the area under the ROC curve was not statistically different when the control group consisted of patients with medium (CA125: 0.939, HE4: 0.928) or high (CA125: 0.939, HE4: 0.931) risk of ovarian cancer. This evidence concerns the gene WFDC2 and ovarian carcinoma.